Description:

Technology is accelerating knowledge discovery and unlocking exciting new opportunities in biomedical research. In this webinar, you will learn how Causaly Cloud is transforming drug development for some of the world’s leading businesses - businesses like Gilead and Novartis - and how it can make an impact on your R&D value chain.

Watch now to find out:

• How to generate AI-driven hypotheses on targets, pathways, biomarkers, and much more by connecting seemingly unconnected concept.
• How our solution characterizes papers in terms of supporting or contradicting a specific causal relationship, presenting the whole picture on a given topic.
• How Causaly Cloud uses machine reading to comprehend all biomedical documents in seconds, extracting precise evidence from millions of sources.

Speakers:

Yiannis Kiachopoulos
Co-founder CEO
Causaly

Yiannis is a computer scientist and language enthusiast, and has consulted with the world’s largest companies for more than 10 years. Yiannis holds a Bachelor and Master in Computer Science, an MBA from Hong Kong University of Science and Technology and took part in Singularity University’s Future Studies program.

Stavroula Ntoufa
Head of Science
Causaly

Stavroula is a Molecular Biologist and Geneticist, with a strong background in immunology, haematology and oncology. She holds a PhD from the University of Athens and has spent 13 years working in EU-funded multicentre research projects in Uppsala University, Università Vita-Salute San Raffaele, and CERTH. Stavroula has published her work in high-impact international journals.

Richard Harrison
Chief Scientist
Causaly

Richard has 35 years’ experience in pharmaceutical research and consulting. Previously he worked at Accenture, where he was a Senior Manager in the Research Domain and was responsible for IT solutions and platform innovations for pharmaceutical clients. Richard also worked as Chief Scientific Officer at Thomson Reuters (later Clarivate Analytics) and has pharmaceutical research experience spanning companies such as Merck, Aventis, and Novartis. In addition, Richard was a founding scientist in two biotech companies, and holds a Ph.D. in Physical Organic Chemistry from Rutgers University.

Founded in 2018, Causaly’s mission is to transform how humans can find, visualize and interpret biomedical knowledge, to accelerate solutions for some of the greatest challenges we face in human health. Causaly acts as an operating system for biomedical and health data that empowers researchers to effortlessly identify new research avenues and innovative drug development opportunities. Its technology mimics human reading, and digests tens of millions of documents into an Enterprise Knowledge Graph allowing researchers and decision-makers to answer questions they can’t answer anywhere else.